Back to news

CVS Health study highlights GLP-1 benefits and the affordability challenge

PR Newswire•15/11/2026•10:00 ET
6

Key Highlights

  • ➤GLP-1 use linked to better outcomes, lower hospital use and lower medical spending
  • ➤Current pharmacy prices exceed observed medical savings across the study population
  • ➤Approximately $350 monthly net price would balance spending over three years
  • ➤More than 137 million U.S. adults medically eligible for semaglutide across indications

Expert Statements

Amy Compton-Phillips, M.D.

“GLP-1s are remarkably effective medicines, and the health benefits are real. The challenge is making those benefits affordable at scale.”

Amy Compton-Phillips, M.D.

“That means getting treatment to the people most likely to benefit, helping them stay on therapy and bringing the price to a level that supports broader access.”

CVS Health study highlights GLP-1 benefits and the affordability challenge PR Newswire

Real-world analysis finds better outcomes and lower medical spending, but current prices limit the full economic value

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in